Adaptimmune Therapeutics plc

  • Home
  • Our Company
    • Overview arrow_forward
    • Partners arrow_forward
    • Board of Directors arrow_forward
    • Leadership Team arrow_forward
    • Scientific Advisory Board arrow_forward
  • Pipeline
    • Clinical Pipeline arrow_forward
    • Afami-cel arrow_forward
    • ADP-A2M4CD8 arrow_forward
    • Preclinical Pipeline arrow_forward
  • Technology
    • Overview arrow_forward
    • Manufacturing arrow_forward
    • Publications arrow_forward
  • Patients & Families
    • Overview arrow_forward
    • Taking Part in Our Clinical Trials arrow_forward
    • Cancer Info arrow_forward
    • Videos arrow_forward
    • Engagement with Patient Organizations arrow_forward
  • Clinical Trials
    • Overview arrow_forward
    • Expanded Access Policy arrow_forward
  • Investors & Media
    • Overview arrow_forward
    • News Center arrow_forward
    • Financial Info and Governance arrow_forward
    • Stock Data arrow_forward
    • SEC Filings arrow_forward
  • Contact
  • Careers
    • Overview arrow_forward
    • US Careers arrow_forward
    • UK Careers arrow_forward

Press Releases

Investors & Media

Investors & Media

  • Overview
  • News Center
    • Media
    • Corporate Presentations
    • Press Releases
    • Publications
    • Events
    • Email Alerts
  • Financial Info and Governance
    • General Meeting (merger)
    • Company Information
    • Leadership Team
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Annual Shareholder Meeting
    • FAQ
    • Contacts
    • Adaptimmune Ltd Report
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • News Center

  • Media
  • Corporate Presentations
  • Press Releases
  • Publications
  • Events
  • Email Alerts
Jul 28, 2016 11:25am EDT

Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma

Jul 26, 2016 8:00am EDT

Adaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma

Jun 21, 2016 7:30am EDT

Adaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific’s Dynabeads™ CD3/CD28 Cell Therapy System

Jun 20, 2016 9:30am EDT

Adaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR™ T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma

Jun 16, 2016 11:00am EDT

Adaptimmune to Present at the 2016 JMP Life Sciences Conference

Jun 05, 2016 9:05am EDT

Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR™ T-Cells in Multiple Cancers at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting

Jun 02, 2016 11:30am EDT

Adaptimmune to Present at the Jefferies 2016 Healthcare Conference

May 24, 2016 7:32am EDT

Adaptimmune Announces Succession Plan for Chairman at End of 2016

May 24, 2016 7:30am EDT

Adaptimmune Strengthens Board with Appointment of Barbara Duncan

May 19, 2016 9:00am EDT

Adaptimmune to Present at the 2016 UBS Global Healthcare Conference

RSS
  • Prev
  • 1...
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • Next
Adaptimmune Therapeutics plc
Privacy Policy Disclaimer Search Sitemap Terms of Use Supply Terms Cookie Policy Manage Cookie Preferences
Linedin Twitter Youtube
© 2023 Adaptimmune Therapeutics plc. All Rights Reserved.